{"id":"sr57746a","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, SR57746A reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"SR57746A is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:01.347Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT00603577","phase":"PHASE3","title":"Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens","status":"TERMINATED","sponsor":"Sanofi","startDate":"2008-01","conditions":"Colorectal Neoplasms","enrollment":102},{"nctId":"NCT00305188","phase":"PHASE3","title":"Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-12","conditions":"Metastases, Colorectal Neoplasms, Colorectal Carcinoma","enrollment":879},{"nctId":"NCT00103649","phase":"PHASE3","title":"18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-11","conditions":"Alzheimer Disease","enrollment":1306},{"nctId":"NCT00104013","phase":"PHASE3","title":"Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-11","conditions":"Alzheimer Disease","enrollment":1455},{"nctId":"NCT00272051","phase":"PHASE3","title":"XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-07","conditions":"Metastases, Colorectal Neoplasms, Colorectal Carcinoma","enrollment":620}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"HAEMATURIA TRAUMATIC"},{"count":1,"reaction":"TYPE 1 DIABETES MELLITUS"}],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SR57746A","genericName":"SR57746A","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SR57746A is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}